Career opportunities for top experts presented at Novartis Career Breakfast
- At the Novartis Career Breakfast, natural science experts working abroad become acquainted with career opportunities offered in their home environment.
- The Novartis Career Breakfast is an effective and award-winning initiative focusing on luring Slovenian top experts to return to their home environment.
- This was the fourth consecutive career breakfast. To date, more than 200 experts have attended the event, 15 of them are now working at Novartis in Slovenia.
Today, more than fifty top natural science experts working or studying abroad have gathered at Lek in Mengeš where they learned about the work and challenges in a high-tech pharmaceutical company in an informal and relaxed atmosphere. The Novartis Career Breakfast is organized in collaboration with the Public Scholarship, Development, Disability and Maintenance Fund of the Republic of Slovenia.
In discussions with leaders and HR managers from Novartis units in Slovenia, the participants of the Novartis Career Breakfast learn about the many opportunities they may meet in a high-tech pharmaceutical company, some of them are also given an initial job interview. The experts who study or work abroad usually decide to return when they realize that they will be able to pursue their professional ambitions also in their home environment. At the event, they have the opportunity to learn about the excellent career opportunities in their home environment and gain a very tangible insight into the wide range of challenges that experts at all Novartis divisions in Slovenia face.
»At this fourth Novartis Career Breakfast in a row, we presented the guests numerous opportunities that are often a key factor that leads to a decision to return to their home environment. The number of participants confirms that we are on the right track and that it is our duty as an employer to appropriately address those human resources that we need and want. Therefore, we will continue to look for innovative ways of how to present job opportunities and particularly opportunities for pursuing career ambitions in our company and thus retain domestic knowledge and talents in Slovenia,« said Samo Roš, member of the Board of Management and Director of Human Resources at Lek.
In the pharmaceutical industry, new career opportunities are continuously emerging and enabling young professionals to grow and develop. To provide such opportunities at home is a challenge. The Novartis Career Breakfast is an event where the participants can obtain first-hand information from the employees: »I had some interesting informal discussions and got acquainted with the work in individual departments; it was probably this that influenced my decision to find my future job at Lek,« said Rok Gaber, PhD, a scientist at Drug Product Development BPD Mengeš, one of the fifteen past participants who have been recruited at Novartis in Slovenia through this initiative.
Rok Brišar, PhD, a technologist at Drug Substance Bioproduction Mengeš, remembers: »Novartis Career Breakfast is a great opportunity to meet company’s executives and make contacts that help you in your future career. I returned to Slovenia because I want to do things I like doing and learn as much as possible through my work. Lek or Novartis in Slovenia certainly enables this. I have identified a number of opportunities to work in various fields as well as for my development and learning. These opportunities are extremely broad as we are a stable and growing company, integrated into the Novartis international network which I like in particular. Conditions for professional and personal growth are good, and a favorable balance between work and private life contributes to our work motivation.«
The event at the Mengeš site has been organized for the fourth time in a row, this time it has brought together more than fifty participants.
Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 2 billion since 2003. More than half of this investment has been devoted to development, and the rest to modernize and expand our production capacities.
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1,000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 1 billion people globally and we are finding innovative ways to expand access to our latest treatments. About 125 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
For additional information contact:
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32